ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Recent advances in molecular mechanisms of microRNAs in pathogenesis and resistance of treatment in glioblastoma.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive brain cancer with poor prognosis, even with current treatments combining surgery, chemotherapy, and radiation. Despite initial tumor removal, recurrence is common and driven by altered genetic profiles. MicroRNAs (miRNAs), small non-coding RNAs with regulatory roles, are implicated in GBM progression through their influence on key hallmarks such as angiogenesis, proliferation, immune evasion, and resistance to therapy. This review systematically analyzed peer-reviewed literature from 2019 to 2025 to evaluate recent findings on miRNAs in GBM pathogenesis. Studies reveal differential miRNA expression in GBM models and their involvement in tumor biology via modulation of target genes. Understanding miRNA networks, along with the tumor microenvironment and immune interactions, may enable the identification of diagnostic and therapeutic biomarkers. Targeting both tumor and associated immune components presents a promising direction for future GBM therapies.
Indexed as
Identifiers
40553401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.